Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist currently in Phase 3 clinical trials for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. The company also develops Atumelnant, an investigational oral nonpeptide ACTH receptor antagonist for conditions like congenital adrenal hyperplasia and Cushing's disease, and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. Additionally, Crinetics is working on antagonists of the parathyroid hormone receptor for primary hyperparathyroidism, thyroid-stimulating hormone receptor antagonists for Graves' disease, and oral nonpeptide GLP-1 and GIP programs for obesity.

Crinetics Pharmaceuticals is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol CRNX. Its securities trade in United States Dollars (USD), reflecting its primary listing in the U.S. equity market. The company is headquartered in the United States, and its shares are accessible to investors through major brokerage platforms that trade on the Nasdaq exchange.

Crinetics Pharmaceuticals operates within the Healthcare sector, specifically in the Biotechnology industry. As a clinical-stage biotechnology company, it focuses on developing novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its research and development efforts center on oral nonpeptide molecules targeting hormone receptors, such as somatostatin, ACTH, and parathyroid hormone receptors, distinguishing it from many peptide-based therapies. The biotechnology industry is characterized by high research intensity, long development timelines, and significant regulatory oversight, and Crinetics is advancing multiple programs through preclinical and clinical stages.

Crinetics Pharmaceuticals is headquartered in the United States, as indicated by its country and region classification (US). The company primarily serves the U.S. market but has international collaborations, including an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan. Additionally, it has a partnership with Cellular Longevity, Inc. for the development and commercialization of CRN01941, a somatostatin receptor type 2 agonist. These partnerships extend its reach to Japanese and potentially other global markets, though its core operations and clinical trials are based in the United States.

As a clinical-stage pharmaceutical company, Crinetics Pharmaceuticals does not yet have approved products generating commercial revenue. Its business model focuses on discovering and developing novel therapeutics for rare endocrine diseases and endocrine-related tumors, with the goal of eventually obtaining regulatory approval and commercializing these drugs. The company generates revenue primarily through collaboration agreements, such as its partnership with Sanwa Kagaku Kenkyusho Co., Ltd for Paltusotine in Japan and with Cellular Longevity, Inc. for CRN01941. These collaborations may include upfront payments, milestone payments, and royalties on future sales. Crinetics also relies on equity financing, grants, and other funding sources to support its research and development activities until it can bring a product to market.